A randomized interventional clinical trial assessing the safety and effectiveness of PeaNoc XL tablets in managing joint pain and inflammation in arthritis patients.

Background: Globally, alternative medicine is used widely by most patients for several health challenges. To evaluate the effectiveness and safety of PeaNoc XL Tablet in managing pain and inflammation, a randomized clinical trial and systematic study was designed. PeaNoc XL Tablet has been widely utilized for pain and inflammation management, but no previous studies have examined its efficacy and safety. The aim of this study was to determine the clinical effectiveness and safety profile of PeaNoc XL in patients with arthritis experiencing joint pain and inflammation. Methods: A randomized, controlled, and an open-label trial was conducted. A total of 155 patients (18 to 60 years) with arthritis were enrolled for participation. Using computer-generated random sequences, the study population was divided into two groups in a randomized manner. Group A received Standard therapy and Group B received Standard therapy with PeaNoc XL Tablet 400mg (two tablets OD after food). Results: Out of 155 patients, a total of 83 individuals were excluded from the study, leaving 72 patients who were randomly assigned to either Group A (n=36) or Group B (n=36). The administration of PeaNoc XL as an adjunct to standard therapy resulted in a significant reduction in levels of TNF-α (P<0.01), IL-1ß (P<0.001), IL-6 (P<0.01), and CRP (P<0.01) in arthritis patients experiencing joint pain and inflammation. Conversely, no notable differences were observed from the baseline in the standard therapy group. Conclusions: After 12 weeks of supplementation of PeaNoc XL tablets, as an add-on therapy helps in the reduction of pain score, joint stiffness, and physical stiffness. Trial registration:  CTRI/2022/10/046693.

Novel Essential Oils Blend as a Repellent and Toxic Agent against Disease-Transmitting Mosquitoes.

Bio-insecticidal research has focused on long-term vector control using essential oils (EOs). This study examined the larvicidal, oviposition-deterrent, and repellent properties of five medicinal herb-based EO formulations (EOFs) on mosquitoes that are vectors of dengue, filariasis, and malaria. EOFs were significantly more toxic to the larvae and pupae of Culex quinquefasciatus, Anopheles stephensi, and Aedes aegypti with LC50 = 9.23, 12.85, and 14.46 ppm, as well with 10.22, 11.39, and 12.81 ppm, with oviposition active indexes of -0.84, -0.95, and -0.92, respectively. Oviposition-deterrent repellence was found in 91.39%, 94.83%, and 96.09%. EOs and N, N-Diethyl-3-methylbenzamide (DEET) were prepared at various concentrations for time duration repellent bioassays (6.25-100 ppm). Ae. aegypti, An. stephensi, and Cx. quinquefasciatus were monitored for 300, 270, and 180 min, respectively. At 100 ppm, EOs and DEET had comparable repellence in terms of test durations. EOF's primary components d-limonene (12.9%), 2,6-octadienal, 3,7-dimethyl, (Z) (12.2%), acetic acid, phenylmethyl ester (19.6%), verbenol (7.6%), and benzyl benzoate (17.4%) may be combined to make a mosquito larvicidal and repellant equivalent to synthetic repellent lotions. In the molecular dynamics simulations, limonene (-6.1 kcal/mol) and benzyl benzoate (-7.5 kcal/mol) had a positive chemical association with DEET (-6.3 kcal/mol) and interacted with the OBP binding pocket with high affinity and stability. This research will help local herbal product manufacturers and the cosmetics industry in developing 100% herbal insect repellent products to combat mosquito-borne diseases, including dengue, malaria, and filariasis.

Pro-inflammatory cytokine molecules from Boswellia serrate suppresses lipopolysaccharides induced inflammation demonstrated in an in-vivo zebrafish larval model.

BACKGROUND: Boswellia serrate is an ancient and highly valued ayurvedic herb. Its extracts have been used in medicine for centuries to treat a wide variety of chronic inflammatory diseases. However, the mechanism by which B. serrata hydro alcoholic extract inhibited pro-inflammatory cytokines in zebrafish (Danio rerio) larvae with LPS-induced inflammation remained unknown. METHODS: LC-MS analysis was used to investigate the extract's phytochemical components. To determine the toxicity of B. serrata extract, cytotoxicity and embryo toxicity tests were performed. The in-vivo zebrafish larvae model was used to evaluate the antioxidant and anti-inflammatory activity of B. serrata extract. RESULTS: According to an in silico study using molecular docking and ADMET, the compounds acetyl-11-keto-boswellic and 11-keto-beta-boswellic acid present in the extract had higher binding affinity for the inflammatory specific receptor, and it is predicted to be an orally active molecule. In both in-vitro L6 cells and in-vivo zebrafish larvae, 160 µg/mL concentration of extract caused a high rate of lethality. The extract was found to have a protective effect against LPS-induced inflammation at concentrations ranged between 10 and 80 µg/mL. In zebrafish larvae, 80 µg/mL of treatment significantly lowered the level of intracellular ROS, apoptosis, lipid peroxidation, and nitric oxide. Similarly, zebrafish larvae treated with B. serrata extract (80 µg/mL) showed an increased anti-inflammatory activity by lowering inflammatory specific gene expression (iNOS, TNF-α, COX-2, and IL-1). CONCLUSIONS: Overall, our findings suggest that B. serrata can act as a potent redox scavenger against LPS-induced inflammation in zebrafish larvae and an inhibitor of specific inflammatory genes.